From Metabolic Syndrome To Cachexia: What’S New About Metabolic Biomarkers ?

Date : Since 01/08/2019

Place : Montigny le Bretonneux

Bioreagents

written by Odile Viltart and Virginie Tolle, PhD - INSERM UMR894 – Centre de Psychiatrie et Neurosciences, Paris, FRANCE

Metabolic syndrome (MetS) is the constellation of risks namely abdominal obesity, insulin-resistance, type 2 diabetes, dyslipidemia and arterial hypertension. In this article, our experts are reviewing a brief history of metabolic syndrome, the importance of biomarkers for the diagnosis and prognosis of nutritional/metabolic disorders and the challenge of identifying new biomarkers

Read the scientific publication >>

Top

My account

Connect or create an account

Bioreagent

Search Products
- Products
- Research domains
- Resources
- News
- About us

Any project? Any challenge? We are in!
+33 (0)139 306 036
Any questions? Contact us

Headquarters :
Parc d’Activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux - France
View our other locations

Bertin Bioreagent

Made by